首页> 外文OA文献 >Systematic Endobronchial Ultrasound-guided Mediastinal Staging Versus Positron Emission Tomography for Comprehensive Mediastinal Staging in NSCLC Before Radical Radiotherapy of Non-small Cell Lung Cancer A Pilot Study
【2h】

Systematic Endobronchial Ultrasound-guided Mediastinal Staging Versus Positron Emission Tomography for Comprehensive Mediastinal Staging in NSCLC Before Radical Radiotherapy of Non-small Cell Lung Cancer A Pilot Study

机译:系统性支气管内超声引导下纵隔分期与正电子发射断层扫描相结合,用于非小细胞肺癌根治性放疗前NsCLC全面纵隔分期的初步研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite known limitations of positron emission tomography (PET) for mediastinal staging of non-small cell lung cancer (NSCLC), radiation treatment fields are generally based on PET-identified disease extent. However, no studies have examined the accuracy of FDG-PET/CT on a per-node basis in patients being considered for curative-intent radiotherapy in NSCLC.In a prospective trial, patients with NSCLC being considered for definitive thoracic radiotherapy (± systemic chemotherapy) underwent minimally invasive systematic mediastinal evaluation with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) following noninvasive staging with integrated PET-CT.Thirty patients underwent EBUS-TBNA, with TBNA performed from a mean 2.5 lymph node (LN) stations per patient (median 3, range 1-5). Discordant findings between PET-CT and EBUS-TBNA were observed in 10 patients (33%, 95% CI 19%-51%). PET-occult LN metastases were demonstrated by EBUS in 4 patients, whereas a lesser extent of mediastinal involvement, compared with FDG-PET, was demonstrated by EBUS in 6 patients, including 2 patients downstaged from cN3 to pN2. LNs upstaged by EBUS were significantly smaller than nodes downstaged by EBUS, 7.5 mm (range 7-9) versus 12 mm (range 6-21), P = 0.005.A significant proportion of patients considered for definitive radiotherapy (+/-chemotherapy) undergoing systematic mediastinal evaluation with EBUS-TBNA in this study have an extent of mediastinal NSCLC involvement discordant with that indicated by PET-CT. Systematic EBUS-TBNA may aid in defining the extent of mediastinal involvement in NSCLC patients undergoing radiotherapy. Systematic EBUS-TBNA has the potential to contribute significantly to radiotherapy planning and delivery, by either identifying occult nodal metastases, or demonstrating FDG-avid LNs to be disease-free.
机译:尽管正电子发射断层扫描(PET)在非小细胞肺癌(NSCLC)的纵隔分期中存在已知的局限性,但放射治疗领域通常基于PET识别的疾病范围。然而,目前尚无研究针对非小细胞肺癌中考虑行根治性放疗的患者按结点检查FDG-PET / CT的准确性。在一项前瞻性试验中,非小细胞肺癌患者应考虑进行确定性胸腔放疗(±系统化疗) )在无创分期PET-CT分期后,通过支气管内超声引导下经支气管针抽吸术(EBUS-TBNA)进行微创系统纵隔评估.30例患者行EBUS-TBNA,每例平均2.5个淋巴结(LN)站进行TBNA患者(中位数3,范围1-5)。在10例患者中观察到PET-CT与EBUS-TBNA之间的不一致结果(33%,95%CI 19%-51%)。 EBUS在4例患者中证实了PET隐匿性LN转移,而EBUS在6例患者中证实了纵隔受累程度较FDG-PET少,其中2例患者从cN3降级至pN2。经EBUS降级的淋巴结明显小于经EBUS降级的淋巴结,分别为7.5 mm(范围7-9)与12 mm(范围6-21),P。= 0.005。在本研究中接受EBUS-TBNA进行系统纵隔评估的患者,其纵隔NSCLC受累程度与PET-CT所显示的程度不一致。系统性EBUS-TBNA可能有助于确定接受放疗的NSCLC患者的纵隔受累程度。系统性EBUS-TBNA可以通过识别隐匿性淋巴结转移或证明FDG-avid LN无病,从而对放射治疗的计划和实施做出重大贡献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号